Company Filing History:
Years Active: 1991
Title: The Innovations of Benjamin Shalita
Introduction
Benjamin Shalita is a notable inventor based in Ramat Hagolan, Israel. He has made significant contributions to the field of medicine, particularly in the treatment of renal osteodystrophy. His innovative approach has led to the development of a unique patent that addresses critical health issues.
Latest Patents
Shalita holds a patent for a method and composition aimed at improving the treatment of human renal osteodystrophy. This patent, titled "Combination of cholecalciferol derivatives for the treatment of renal," involves the administration of 6-40 mcg/d of 24,25(OH)₂D₃ in combination with 1-alpha(OH)D₃ or 1,25(OH)₂D₃ or DHT₂. The method ensures that patients maintain calcium concentrations in the serum at 10-11 mg/dl and phosphate concentrations at 5.5-6.0 mg/dl, with a numerical multiplication product of calcium x phosphate not exceeding 60-65.
Career Highlights
Shalita is currently associated with Teva Pharmaceutical Industries Limited, a leading global pharmaceutical company. His work at Teva has allowed him to focus on innovative treatments that can significantly improve patient outcomes in renal health.
Collaborations
Throughout his career, Benjamin Shalita has collaborated with esteemed colleagues, including Mordecai Popovtzer and Ben Z Weiner. These collaborations have fostered an environment of innovation and have contributed to the advancement of medical treatments.
Conclusion
Benjamin Shalita's contributions to the field of medicine through his patent and work at Teva Pharmaceutical Industries Limited highlight his commitment to improving health outcomes. His innovative methods in treating renal osteodystrophy showcase the importance of research and development in the pharmaceutical industry.